勃罗马龙与罗醇使用者的缺血性中风风险:使用TriNetXX的现实世界队列研究
Shih-Wei Lai1,2, Kuan-Fu Liao3
1School of Medicine, China Medical University, Taichung, Taiwan. wei@mail.cmuh.org.tw.
Clinical rheumatology
|December 9, 2025
概括
在患有高尿血症或痛风的个体中,本兹布罗马龙的使用与与阿洛普林醇相比,缺血性中风的风险更高. 这项研究突出了这些尿酸降低疗法的长期安全性概况的潜在差异.
科学领域:
- 心血管流行病学心血管流行病学
- 药物监督 药物监督 药物监督
- 类风湿病学 类风湿病学
背景情况:
- 勃罗马龙和阿洛普林醇是治疗高尿素血和痛风的尿酸降低疗法.
- 这些药物之间缺血性中风的比较风险尚未得到充分确立.
研究的目的:
- 在20-84岁的患者中,比较与勃罗马龙与罗醇相关的缺血性中风风险.
- 评估这些尿酸降低药物对缺血性中风风险的长期安全性.
主要方法:
- 使用TrinetX网络数据 (2006-2024) 的回顾性队列研究.
- 基于人口统计和并发症的1,1匹配使用博马龙或普林醇的个体.
- 计算了未调整的风险比率和调整的危险比率 (Cox回归).
主要成果:
- 这项研究包括每个匹配组中的26,510人.
- 与布罗马龙 (1.179%) 相比,布罗马龙的使用与缺血性中风 (1.375%) 的累积发病率更高.
- 调整后的1.296的危险比率 (95% CI: 1.129-1.488) 表明,使用博马龙,缺血性中风的风险在统计上显著增加.
结论:
- 勃罗马龙的使用与长期缺血性中风的风险相比,与罗醇的长期风险显著更高.
- 这些发现表明,博马龙可能会增加缺血性中风风险,为临床决策提供信息.
- 这项研究强调了在选择尿酸降低疗法时考虑中风风险的重要性.
相关概念视频
01:29Therapeutic Drug Monitoring: Affecting Factors
182
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
182
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
135
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
135
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
382
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
382
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
01:26Atherosclerosis III: Management
296
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
296